Therapeutic Potential for Aldosterone Inhibition in Duchenne Muscular Dystrophy

PHASE3CompletedINTERVENTIONAL
Enrollment

52

Participants

Timeline

Start Date

March 20, 2015

Primary Completion Date

May 31, 2018

Study Completion Date

May 31, 2018

Conditions
Duchenne Muscular Dystrophy
Interventions
DRUG

Eplerenone

26 Subjects will take Eplerenone, one 50mg capsule by mouth once daily for 12 months.

DRUG

Spironolactone

26 Subjects will take Spironolactone, one 50mg capsule by mouth once daily for 12 months.

Trial Locations (6)

37212

Vanderbilt University Medical Center, Nashville

43210

The Ohio State University Medical Center, Columbus

66103

University of Kansas Medical Center, Kansas City

80045

University of Colorado, Aurora

84113

University of Utah, Salt Lake City

90095-1743

Mattel Children's Hospital and David Geffen School of Medicine at UCLA, Los Angeles

All Listed Sponsors
collaborator

University of California, Los Angeles

OTHER

collaborator

University of Utah

OTHER

collaborator

University of Colorado, Denver

OTHER

collaborator

University of Kansas Medical Center

OTHER

collaborator

Vanderbilt University Medical Center

OTHER

lead

Ohio State University

OTHER

NCT02354352 - Therapeutic Potential for Aldosterone Inhibition in Duchenne Muscular Dystrophy | Biotech Hunter | Biotech Hunter